Mutations in the gene for the latent transforming growth factor beta binding protein 4 (LTBP4) cause autosomal recessive cutis laxa type 1C. To understand the molecular disease mechanisms of this disease, we investigated the impact of LTBP4 loss on transforming growth factor beta (TGFβ) signaling. Despite elevated extracellular TGFβ activity, downstream signaling molecules of the TGFβ pathway, including pSMAD2 and pERK, were down-regulated in LTBP4 mutant human dermal fibroblasts. In addition, TGFβ receptors 1 and 2 (TGFBR1 and TGFBR2) were reduced at the protein but not at the ribonucleic acid level. Treatment with exogenous TGFβ1 led to an initially rapid increase in SMAD2 phosphorylation followed by a sustained depression of phosphorylation and receptor abundance. In mutant cells TGFBR1 was co-localized with lysosomes. Treatment with a TGFBR1 kinase inhibitor, endocytosis inhibitors or a lysosome inhibitor, normalized the levels of TGFBR1 and TGFBR2. Co-immunoprecipitation demonstrated a molecular interaction between LTBP4 and TGFBR2. Knockdown of LTBP4 reduced TGFβ receptor abundance and signaling in normal cells and supplementation of recombinant LTBP4 enhanced these measures in mutant cells. In a mouse model of Ltbp4 deficiency, reduced TGFβ signaling and receptor levels were normalized upon TGFBR1 kinase inhibitor treatment. Our results show that LTBP4 interacts with TGFBR2 and stabilizes TGFβ receptors by preventing their endocytosis and lysosomal degradation in a ligand-dependent and receptor kinase activity-dependent manner. These findings identify LTBP4 as a key molecule required for the stability of the TGFβ receptor complex, and a new mechanism by which the extracellular matrix regulates cytokine receptor signaling.
Introduction
The extracellular matrix (ECM) is essential for the storage, presentation and contextualization of cytokines, including members of the transforming growth factor beta (TGFβ) superfamily (1) . Fibrillin microfibrils, either as independent structures or as a part of elastic fibers, bind latent TGFβ-binding proteins (LTBPs), which are large secreted glycoproteins that regulate the bioavailability of TGFβ (2) . Four LTBPs have been identified to date. An induced mutation in Ltbp4 causes a severe multi-system disorder in mice (3) . Similarly, LTBP4 (OMIM 604710) mutations lead to autosomal recessive cutis laxa type 1C (ARCL1C, OMIM 613177) in humans, a disease associated with developmental emphysema and cardiovascular, gastrointestinal, genitourinary and musculoskeletal anomalies (4) . At the molecular level, LTBP4 deficiency causes abnormal elastic fiber formation and abnormal TGFβ activity (3) (4) (5) (6) . However, the molecular mechanisms leading to these changes are poorly understood, and their relative contribution to the overall disease phenotype remains unclear.
In previous studies, we observed elevated extracellular TGFβ activity in cells from patients with ARCL1C (4, 5) . Similarly, excessive canonical and non-canonical TGFβ signaling has been reported in Marfan syndrome (7, 8) , caused by fibrillin-1 (FBN1) mutations, in Loeys-Dietz syndrome (9) , caused by TGFBR1 or TGFBR2 mutations and in autosomal dominant cutis laxa, caused by mutations in the elastin gene (10, 11) . Thus, dysregulated TGFβ activity has been considered to be an important mechanism underlying connective tissue disorders, with therapeutic implications to the treatment of Marfan syndrome (12) .
The regulation of TGFβ activity and signaling occurs at the level of the activation of the cytokine through its release from latent forms sequestered in the ECM, extracellular presentation of the growth factors by co-receptors, modulation of the activity and abundance of the TGFβ receptor (TGFBR) complex by phosphorylation, protein-protein interactions, endocytosis and proteolysis (13) . The role of TGFβ receptor endocytosis in signaling is a major focus of investigations (14) . However, it remains unclear if the quality of the ECM surrounding the cell can influence this process.
In this study, we find that skin fibroblasts with loss-of-function mutations in LTBP4 have depressed intracellular signaling despite elevated extracellular TGFβ activity. Treatment of these cells with exogenous TGFβ causes a rapid decline in intracellular signaling. In the absence of LTBP4, TGFBR1 and TGFBR2 are internalized and degraded by lysosomes in a ligand and receptor activity dependent manner. We demonstrate a molecular interaction between LTBP4 and TGFBR2 and show that TGFβ receptor levels and activity are dependent on Ltbp4 in vivo. These findings uncover a new mechanism by which LTBP4, and more broadly, the ECM, regulates TGFβ activity.
Results

Loss-of-function LTBP4 mutations in patients with ARCL1C
DNA sequencing was performed in Patients 4-6 and the parents of Patient 7 to identify new mutations in the LTBP4 gene. Patients 4-6 showed the characteristic clinical and pathological hallmarks of ARCL1C (Fig. 1A-D) and had compound heterozygous mutations representing two nonsense, two frameshift, one splice site and one missense mutations (Table 1 and Fig. 1E ). In addition, both parents of Patient 7 had an identical splice site mutation and a history of consanguinity. The types and distribution of mutations were similar to previous findings (Fig. 1E ).
Fibroblasts were established from Patients 1 to 3 who carried previously identified premature termination mutations (4) and Patient 5, who was compound heterozygous for a cysteine substitution missense mutation and a frameshift mutation (Table 1) . Mutant fibroblasts were compared with control fibroblasts 1-4. The characteristics of the fibroblasts and the demographic details of the donors are shown in Table 2 . Mutant fibroblasts, on average, had an 80% reduction of LTBP4 messenger ribonucleic acid (mRNA) levels (P < 0.001) by quantitative polymerase chain reaction (qPCR) ( Fig. 2A ) and no detectable LTBP4 protein was observed by immunoblotting (IB) of conditioned media (Fig. 2B ). In addition, higher levels of total and active TGFβ were observed in the conditioned media of LTBP4 mutant fibroblasts compared controls ( Fig. 2C and D ; P < 0.001), with no difference in the mRNA levels of TGFB1, the main TGFβ isoform produced by skin fibroblasts (Fig. 2E) . These results suggest reduced sequestration of TGFβ in the ECM of mutant cells, consistent with earlier data obtained with different sets of LTBP4 mutant and control fibroblasts (4,5).
Reduced TGFβ signaling in mutant cells
To study the downstream signaling triggered by increased extracellular TGFβ, both the canonical and the non-canonical pathways were tested. Additionally, cellular signals triggered by TGFβ1 and TGFBR1 kinase inhibitor treatments were studied. Despite elevated extracellular TGFβ activity, LTBP4 mutant cells had decreased levels of SMAD2 and ERK phosphorylation compared with the controls in pilot experiments using cells from Control 3 and Patient 5 (Fig. 3) . As expected, TGFβ treatment increased the phosphorylation of SMAD2 and ERK in both patients and controls, but the difference remained. TGFBR1 inhibitor treatment decreased the phosphorylation of SMAD2 and ERK in controls as expected, but surprisingly increased phosphorylation in patients.
To test if our observations were generalizable, independent of genetic background and demographic variables and statistically significant, we repeated these experiments in our entire panel of patients and controls. A limitation of this set of experiments was that it was not possible to load all samples on a single gel. As the main focus of our studies was the difference between patients and controls, we loaded all patient and control samples for each treatment on a single gel. This allowed us to make legitimate comparisons between patients and controls but not across treatments. Similar to our pilot experiments, we saw decreased SMAD2 phosphorylation in patients at baseline conditions ( Fig. 4A ; P = 0.014). TGFβ supplementation increased the difference in SMAD2 and ERK phosphorylation (Fig. 4B ) between patients and controls (P < 0.05), and TGFBR1 inhibition eliminated the difference (Fig. 4C) . Normalization of pSMAD2 and pERK to SMAD2 and ERK, respectively ( Fig. 4A-C) , did not yield different results from normalization to tubulin (data not shown). Reduced pSMAD2 levels in mutant cells were not accompanied by an increased abundance of either SMAD7 or SMAD6 (Fig. 4D) , known negative feedback regulators of TGFβ signaling. In fact, the levels of both SMAD6 and SMAD7 were decreased, consistent with a reduced transcriptional output of the TGFβ pathway. Thus, we postulated that reduced TGFβ responsiveness in LTBP4 mutant fibroblasts was mediated by a mechanism located upstream of transcriptional feedback inhibition, possibly involving alterations at the level of the TGFβ receptors.
Reduced abundance of the TGFβ receptor complex
No significant difference was found between patients and controls in TGFBR1 and TGFBR2 expression at the mRNA level Human Molecular Genetics, 2015, Vol. 24, No. 14 | 4025 (Fig. 5A) . However, TGFBR1 protein levels were decreased in LTBP4 mutant cells at baseline (Fig. 5B ) and remained reduced relative to controls upon TGFβ supplementation (Fig. 5C ). The level of TGFBR2 in mutant cells at baseline was not significantly different from controls, but TGFβ treatment resulted in a significant reduction (Fig. 5C ). TGFBR1 inhibitor treatment normalized the levels of both TGFBR1 and TGFBR2 in mutant cells (Fig. 5D ). There was no significant difference in TGFBR3 levels between patients and controls under any of the treatment conditions. Phosphorylated TGFBR1 was less abundant in mutant cells both under baseline and TGFβ supplementation conditions, but pTGFBR1 levels were equalized upon inhibitor treatment (Fig. 5 ). In addition, examination of the pTGFBR1/TGFBR1 ratio (data not shown) showed that a similar proportion of the receptor pool was phosphorylated in mutant and control cells under baseline conditions and TGFβ treatment increased the phosphorylation of the receptor pool similarly in both cases and controls. Thus, TGFBR1 phosphorylation occurred appropriately in LTBP4 mutant cells, and a possible reason for reduced TGFβ signaling was an overall reduction of the TGFBR1/TGFBR2 pool.
We next examined the kinetics of response to TGFβ1 (Fig. 6 ). Control cells achieved maximal stimulation of SMAD2 phosphorylation after 90 min of treatment followed by a gradual decrease. In contrast, pSMAD2 levels peaked in mutant cells 30 min after treatment followed by a rapid decay of the signal resulting in a net reduction of SMAD2 signaling as indicated by the area under the curve of the pSMAD2/time kinetic plot. ERK phosphorylation was increased in control cells in a sustained manner, but transiently decreased in mutant cells and subsequently stayed at baseline levels. TGFBR1 levels were noticeably decreased in patient cells at 90 min, whereas TGFBR2 levels were detectably depressed at 30 min and stayed at reduced levels subsequently. Thus, the reduction in TGFBR2 levels preceded and therefore is likely causally related to TGFBR1 depletion and the deficit in SMAD2 phosphorylation in mutant cells.
Molecular interaction between LTBP4 and TGFBR2
As loss of TGFBR2 was one of the earliest events triggered by TGFβ1 treatment in LTBP4 deficient cells, we hypothesized that stabilization of the TGFBR receptor complex by LTBP4 depends on a complex formation between TGFBR2 and LTBP4. To test this, we performed co-immunoprecipitation (Co-IP) experiments by coupling anti-TGFBR2 antibodies to beads and detecting protein complexes by IB for LTBP4. LTBP4 was successfully pulled down by anti-TGFBR2 antibodies in control cells (Fig. 7A) , demonstrating a molecular interaction between these two molecules. LTBP4 mutant samples showed a lack of an immunoprecipitated product demonstrating the specificity of our reagents. Human Molecular Genetics, 2015, Vol. 24, No. 14 | 4027
LTBP4 knockdown and rescue with recombinant LTBP4
We tested if experimental manipulation of LTBP4 levels would support our findings in mutant cells. To knock down LTBP4 expression in skin fibroblasts from a healthy donor (Control 3, Table 2 ), we used an antisense morpholino oligonucleotide (MO) to target the first exon shared by all major transcript isoforms of LTBP4. MO treatment completely abolished the expression of the long isoforms of LTBP4 (LTBP4L, NM_003573 and NM_001042544) and resulted in the diminished expression of the short isoform of LTBP4 (LTBP4S, NM_001042545) and an almost complete skipping of exon 2, which encodes the essential, first epidermal growth factor-like domain in the protein (Fig. 7B ). We next examined LTBP4 protein levels following knockdown by IB (Fig. 7C ). Whereas maximal knockdown was achieved at the mRNA level following a single dose of MO (Fig. 7B) , at the protein level it only achieved a low (8%) reduction. Substantial (60%) knockdown at the protein level required two doses of MO treatment, presumably because of the slow secretion kinetics or low turnover of LTBP4. Therefore, we studied TGFβ signaling in cells treated with a double dose of MO in subsequent experiments (Fig. 7D ). LTBP4 knockdown noticeably decreased TGFBR1, TGFBR2, pSMAD2 and pERK levels ( Fig. 7E ), replicating our findings with LTBP4 mutant cells. We next overexpressed LTBP4 in HEK293 cells using a lentiviral vector, pLOC (Fig. 7F) . A vector expressing red fluorescent protein was used to generate control HEK293 cells. Conditioned media from these two cell lines were used in subsequent experiments. To determine how long it took for LTBP4 mutant human dermal fibroblasts (Patient 2) to respond to recombinant LTBP4, we measured TGFBR2 levels at different time points after treatment using an enzyme-linked immunosorbent assay (ELISA) and found that starting 2 days post-treatment, the abundance of TGFBR2 increased gradually. By 7 days, the TGFBR2 levels peaked (data not shown). We therefore compared the expression of TGFβ receptors and signal transduction molecules by IB after 7 days of treatment ( Fig. 7D and E). The abundances of TGFBR1, TGFBR2, pSMAD2 and pERK were all elevated in cells treated with recombinant LTBP4 compared with controls ( Fig. 7D ). These findings provide evidence that alteration of TGFβ receptor levels in LTBP4 mutant cells was not an epiphenomenon but a consequence of LTBP4 deficiency.
Endocytic regulation of TGFBR1 and TGFBR2
We hypothesized that reduction of the TGFβ receptor pool in the absence of LTBP4 may be caused by increased turnover of the receptors. Following inhibition of protein synthesis by cycloheximide, we observed accelerated decay of both TGFBR1 and TGFBR2 in mutant cells compared with controls by ELISA ( Fig. 8A and B) . To uncover the mechanism of TGFBR1 and TGFBR2 degradation, cells were treated with inhibitors of clathrin-mediated (monodansylcadaverine, MDC) and caveolinmediated endocytosis (filipin). Both treatments normalized the expression of TGFBR1 and TGFBR2 (Fig. 8C and D) . TGFβ1 with or without TGFBR1 inhibition did not induce any differences between control and patient fibroblasts pre-treated with filipin or MDC (data not shown). Thus, we concluded that endocytosis caused the destabilization of TGFBR1 and TGFBR2 in LTBP4-deficient dermal fibroblasts.
Protein degradation commonly occurs in proteasomes or lysosomes (15) . To determine which of these mechanisms were responsible for TGFBR degradation, a proteasome inhibitor, lactacystin, and a lysosome inhibitor, ammonium chloride, were applied to fibroblasts. Ammonium chloride reversed the reduction Human Molecular Genetics, 2015, Vol. 24, No. 14 | 4029 of TGFBR1 and TGFBR2 caused by LTBP4 deficiency (Fig. 8E ), but lactacystin did not (Fig. 8F) . To obtain further evidence of lysosomal degradation of TGFBRs, we performed immunostaining for TGFBR1 and lysosome-associated membrane protein 1 (LAMP1) (Fig. 8G) . In control cells, TGFBR1 showed staining at the periphery of cells, consistent with plasma membrane localization. Conversely, in patient cells, TGFBR1 accumulated in intracellular puncta, frequently co-localized with LAMP1. Thus, both inhibitor treatment and immunostaining studies support the conclusion that in LTBP4 deficient cells, TGFβ receptors are internalized by endocytosis and degraded by lysosomes.
Regulation of TGFBRs by LTBP4 in vivo
To investigate if LTBP4 regulates of TGFβ receptors in vivo, we studied mice with targeted inactivation of the short form of Ltbp4, Ltbp4S
−/− (3,6), which show many of the clinical, pathological and molecular manifestations LTBP4-related cutis laxa (4). Knockout mice and wild-type (WT) littermates were treated at 3-4 weeks of age with saline or with TGFBR1 inhibitor by intraperitoneal injection and were sacrificed 6 h after treatment. We collected skin tissue samples and studied the expression of key TGFβ signaling molecules by IB. Ltbp4S −/− mice showed reduced TGFBR1 and TGFBR2 levels with concomitant reductions in SMAD2 and ERK phosphorylation ( Fig. 9A and B) . TGFBR1 inhibitor treatment partially normalized the expression of these molecules. Thus, we conclude that LTBP4 acts as a regulator of TGFBR levels and signaling in vivo.
Discussion
Our studies highlight a previously unrecognized activity of the ECM molecule, LTBP4, in stabilizing complexes of TGFBR1 and TGFBR2 for sustained signaling in response to TGFβ. In LTBP4 mutant cells, we demonstrated ligand-and receptor kinase activitydependent endocytosis and degradation of TGFβ receptors. Experimental knockdown of LTBP4 destabilized the receptors leading to diminished TGFβ signaling, whereas supplementation with LTBP4 led to stabilization of the receptors. Furthermore, Ltbp4S −/− mice showed deficits in TGFBR abundance and signaling in vivo. Thus, we provide four independent lines of evidence for LTBP4 as a regulator of TGFβ receptor stability and activity. This new function complements known activities of LTBP4 in elastic fiber assembly and TGFβ sequestration (2, 16) and is associated with a molecular interaction between LTBP4 and TGFBR2. The activity of TGFβ receptors is regulated, in part, by segregating the receptor complexes into different endocytic compartments. Endocytosis via clathrin-coated pits into early endosome antigen-1 (EEA1) positive endosomes permits ongoing receptor signaling, whereas segregation into lipid rafts followed by caveolin-mediated endocytosis leads to the degradation of the receptor complex (17) . TGFBR3 enhances TGFβ signaling by serving as a coreceptor of TGFβ and by facilitating the clathrin-mediated endocytosis of TGFBR1 and TGFBR2 (18) . We found that TGFβ receptor degradation in the absence of LTBP4 did not involve shifting the balance of the receptors from clathrin to caveolin-mediated endocytic pathways, as inhibition of either of the pathways stabilized the TGFβ receptor complex. Endocytic elimination of the receptor complex did not involve TGFBR3 either, as TGFBR3 levels remained unchanged in LTBP4 deficient cells.
A known degradation pathway of TGFβ receptors involves recruitment of ubiquitin ligases Smurf1 (19) or Smurf2 (20) to TGFBR1 by SMAD7, causing both proteasomal and lysosomal degradation of the receptor complex. As SMAD7 is a transcriptional target of TGFβ, it serves as a negative feedback to limit the duration and intensity of signaling. As SMAD7 levels were reduced, we propose that TGFβ receptor degradation occurred by a different mechanism in LTBP4 deficient cells. Consistent with this notion, a proteasome inhibitor did not rescue TGFβ receptor loss in mutant cells, but a lysosome inhibitor did. Co-localization of TGFBR1 with LAMP1 in intracellular punctate structures in mutant cells further supported lysosomal targeting of the receptors. Whereas the exact mechanism which marks TGFβ receptors for degradation in the absence of LTBP4 remains unclear, recruitment of sorting nexins, known to traffic TGFβ receptors to lysosomes (21) , is a likely candidate. Alternatively, binding to the ECM through LTBP4 may physically prevent default endocytosis of the receptor complex.
Our Co-IP results are consistent with LTPB4 stabilizing the TGFBR complex either through direct molecular interactions with TGFBR2, or indirectly, as a part of a larger protein complex. As LTBP4 is known to support cell adhesion and bind heparin (22) , this larger complex may include cell surface heparan sulfate proteoglycans, such as TGFBR3 (18) or syndecan-2 (23). However, interaction with monomeric LTBP4 is unlikely to be sufficient for TGFBR stabilization, as the response of cells to LTBP4 supplementation takes at least 2 days, consistent with a requirement of LTBP4 to be incorporated into a complex, multimeric ECM structure.
Our findings are relevant to understanding of the molecular mechanisms and to developing treatments for a range of inherited and complex diseases. ARCL1C is a rare recessive disorder associated with prematurely redundant and inelastic skin and disorganized ECM in the dermis. We suggest that in addition to impaired assembly of the elastic fibers, inadequate signaling by TGFβ, a key driver of ECM gene expression, may exacerbate the pathological alterations in these patients. Consequently, LTBP4-like ligands may be effective in stabilizing the TGFβ receptor complex and allowing for adequate signal intensity and improved ECM production. Alternatively, TGFBR1 inhibition may be effective, as we show that it stabilizes the receptor complex in Ltbp4S knockout mice and TGFBR1 inhibition has been shown to be effective in improving the formation of the alveoli in the same animal model (6) .
It is unclear how TGFBR1 inhibitor treatment results in increased SMAD2 phosphorylation in patient cells and knockout mice. A possible explanation may be that a certain pool of TGFBR1 is inaccessible to the inhibitor and in the absence of receptor degradation this receptor pool is capable of generating pSMAD2. Alternatively, it is possible that TGFBR2 stabilization allows SMAD2 and ERK phosphorylation through another type 1 TGFβ receptor not inhibited by the drug we used.
Several inherited aortic aneurysm syndromes such as Marfan syndrome and Loeys-Dietz syndrome are associated with disorganized vascular ECM and excessive TGFβ signaling (24) . In Loeys-Dietz syndrome, excess TGFβ activity is considered paradoxical, as it is caused by heterozygous loss-of-function mutations in positive regulators of the pathway, such as TGFBR1, TGFBR2, TGFB2 or SMAD3. The current hypothesis to explain these observations is that reduced canonical TGFβ signaling results in the elimination of negative feedback mechanisms leading to excessive non-canonical TGFβ activity (24) . Molecular disease models and treatment approaches for these conditions may be refined by considering the consequences of these mutations and the resulting changes in the ECM for the stability of TGFβ receptors.
Tissue fibrosis is a common consequence of injury and is considered a barrier to repair and functional recovery. It is characterized by increased proliferation of fibroblasts, excessive TGFβ signaling and ECM production (25) . Elevated tissue stiffness is known to serve as a positive feedback mechanism by enhancing integrin-mediated TGFβ activation (26) . Our studies suggest that increased LTBP4-mediated TGFβ receptor stabilization may be an additional positive feedback mechanism in this condition. Indeed, LTBP4 expression is up-regulated in kidney fibrosis and Ltbp4S knockout mice have an attenuated fibrotic response to obstructive nephropathy (27) . In muscular dystrophy, myofibrillar damage results in extensive fibrosis and functional decline. LTBP4 has been identified as a modifying gene of muscular dystrophy in both mice (28) and humans (29) , highlighting its function in modulating fibrosis.
Materials and Methods
Clinical summaries
The subjects or their parents gave written, informed consent to participate in the study, approved by the University of Pittsburgh Institutional Review Board. The clinical details of Patients 1-3 have been published previously (4) . Patient 4, who passed away at the age of 15 months, was a Caucasian male born at 39 weeks gestation with a birth weight of 3969 g (96th percentile) and birth length of 57 cm (100th percentile). The pregnancy was complicated by polyhydramnios and diaphragmatic hernia, which was surgically corrected shortly after birth. Congenital cutis laxa was noted with generalized lax, redundant, inelastic skin, loose facial skin with facial drooping and skin wrinkling. The karyotype was 46, XY. A genetics exam at 3 months also revealed puffy eyes with redundant conjunctivae, flat facial profile, hypertelorism, telecanthus, small mouth with recessed chin, bilateral pre-auricular pits, protruding abdomen with barrel-shaped chest, ear and deep plantar creases and hypotonia. He also had a hooked nose, vocal cord laxity, bilateral orbital fat pad prolapse, kidney stones at 3 months and herniated lungs at 13 months. He had esophageal, duodenal and bladder diverticula as well as surgical repair of bilateral inguinal hernias. The patient was also diagnosed with obstructive sleep apnea, tachypnea, emphysema, heart murmur, pulmonary valve stenosis, arterial tortuosity and esophageal dilatation and tortuosity. A neonatal echocardiogram revealed dysplastic tricuspid, pulmonic and aortic valves with a moderate patent ductus arteriosus and a patent foramen ovale. A repeat echocardiogram at 6 weeks of age showed mild pulmonic stenosis and a patent foramen ovale with no patent ductus arteriosus.
Patient 5 is a 14-year-old Caucasian female born at 38 weeks gestation with a birth weight of 3629 g (86th percentile) and birth length of 53 cm (98th percentile). Congenital cutis laxa was diagnosed at 9 months of age by skin biopsy. Medical history includes myopia, hiatal hernia, decreased exercise tolerance, asthma, lumbar scoliosis and a heart murmur. Her surgical history includes Chiari decompression at age 8 and dental surgery at age 12. Early echocardiograms showed mild branch pulmonary artery stenosis and a pericardial effusion, both of which resolved by age 4. At age 14, she had generalized lax, redundant skin with some skin wrinkling, premature aging of the skin, telangiectasia and mild facial drooping (Fig. 1A) . She had frontal bossing, bitemporal narrowing, prominent ears, lateral flaring synophrys, hooked nose, long philtrum, joint laxity, pectus carinatum, and flat feet. Her most recent echocardiogram revealed a thickened mitral valve with mild bileaflet prolapse, as well as trace aortic, mitral, tricuspid and pulmonic regurgitation. Pulmonary function testing revealed moderate airflow limitation and significantly increased airflow resistance consistent with mild-to-moderate obstructive lung disease. However, because bronchodilator response was not measured, it is unknown whether the airflow limitation was caused by asthma or chronic obstructive pulmonary disease (COPD). Electron microscopic evaluation of a skin biopsy specimen revealed an elastic fiber pathology characteristic of LTBP4-related cutis laxa, with the elastin core of fibers showing large globular aggregates with a smooth surface and a poor integration with surrounding microfibrils (Fig. 1B and C) compared with a control specimen (Fig. 1D) .
Patient 6 is a 20-year-old Caucasian female born at full term with a birth weight of 2920 g (24th percentile) and birth length of 50 cm (69th percentile). Congenital cutis laxa was diagnosed at 10 months and assumed to be an autosomal recessive type. She had generalized transparent, lax, redundant, inelastic, wrinkled and prematurely aged skin with loose facial skin. On exam she had a long philtrum, vocal cord laxity with a hoarse voice, joint laxity, flat feet and scoliosis. The patient's medical history consisted of right ventricular hypertrophy, pulmonary artery stenosis, peripheral pulmonary stenosis and significant pulmonary hypertension. Her aortic root diameter was at the upper limits of normal. There were also multiple bladder diverticula with obstructive uropathy. Glycosylation testing was performed to rule out autosomal recessive cutis laxa type 2A (ARCL2A) and was normal.
Patient 7 was a male proband born by spontaneous delivery at 39 weeks gestation as the first child of consanguineous Turkish parents who were first cousins. The pregnancy was uneventful, Apgar scores were 9/10/10, and birth weight was 3850 g (92nd percentile). The proband died ∼35 years ago at 6 weeks of age following eating and breathing difficulties, hiatal hernia surgery, pneumonia and right heart insufficiency. Medical records indicated extremely lax skin, hypotonia, hyperextensible finger joints, lax knee joints, esophageal and bladder diverticula, intestinal stenosis and ectasia of the left ureter. ECG and X-rays showed a hypertrophic left heart with a suspicion of ventricular septal defect and pulmonary artery stenosis. Karyotype and brain computed tomography were both normal. Both parents and one adult sibling of the proband had mild Ehlers-Danlos syndromelike symptoms, including some lax or hyperelastic skin, mild joint laxity, easy bruising and slow wound healing. Skin biopsies of both parents were also compatible with mild Ehlers-Danlos syndrome. The father, examined at age 60 and a 40-pack-year smoker, had paradontosis, lax elbow skin, flat feet, inguinal hernia with onset at age 60, chronic obstructive bronchitis, bronchiectasis, emphysema and asthma. The mother, also a 35-pack-year smoker, was examined at age 53 and found to have bronchiectasis and emphysema/COPD. She also had dental carries, paradontosis at age 30, mild scoliosis, left eye ptosis, glaucoma and bilateral sensorineural hearing loss that began at age 40. She had an echocardiogram in 2002 that was reportedly normal. The proband's sister had a spontaneous pneumothorax at age 22. Both parents and the sister were heterozygous for mutation c.341-1G>C.
Electron microscopy
Skin biopsies from Patient 5 and a control individual were analyzed as described previously (4).
Mutational analysis
The LTBP4 gene was screened for mutations as described previously (4).
Cell culture
Skin punch biopsies (3-4 mm) were collected. Dermal fibroblast cells were cultured from the biopsies of control individuals and patients (Table 2 ) and were maintained in Dulbecco's modified Eagle's medium supplemented with 100 units/mL penicillin, 0.1 mg/ml streptomycin sulfate, 2.5 μg/mL amphotericin B and 10% fetal bovine serum. All cells were cultured at 37°C in a humidified environment containing 5% CO 2 , and used at passages 5-7.
Reverse transcription polymerase chain reaction
Total ribonucleic acid (RNA) was extracted using TRIzol reagent (Invitrogen) from dermal fibroblasts according to the manufacturer's protocol. Complementary DNA was prepared using a SuperScript III Reverse Transcriptase kit (Invitrogen). For monitoring the efficacy of antisense MO knockdown, the long and short isoforms of LTBP4 (LTBP4L and LTBP4S) were amplified by the following primer pairs: LTBP4S: 5′-GGCCAGAGCTCTACT GAAGC-3′-F, 5′-GCAGCTCCCGAAAGCAGTAA-3′-R; LTBP4L: 5′-C TGCTCTGGGTGTCGCTATT-3′-F, 5′-GCAGCTCCCGAAAGCAGT AA-3′-R. The beta-actin mRNA (ACTB) was amplified as a control using the following primer pair: 5′-TGGAACGGTGAAGGTGACA-3′-F and 5′-AAGGGACTTCCTGTAACAATGCA-3′-R. The products were visualized using agarose gel electrophoresis, ethidium bromide staining and fluorescent gel imaging. We performed qPCR using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Commercial qPCR assays (TaqMan ® Gene Expression Assay) were used to assess the expression of the LTBP4, TGFB1, TGFBR1 and TGFBR2 genes. Data were analyzed using the Sequence Detection System Version 2.4 and Microsoft Excel. GAPDH was used as an endogenous housekeeping control gene for normalization. Experimental samples were run in triplicates where threshold cycle (C t ) measurements were normalized using GAPDH. The relative expression of control and patient fibroblasts was determined using the comparative C t method (2 -ΔΔCt ) (30).
TGFβ activity assay
Mink lung epithelial cells were stably transfected with an expression construct containing a plasminogen activator inhibitor-1 promoter fused to the firefly luciferase gene (31) and used to detect the activity of TGFβ in human fibroblasts using a Luciferase Assay System (Promega). Reporter cells were treated with conditioned media from cultured human fibroblasts for 16 h, lysed in Reporter Lysis Buffer (Promega), and assayed for luciferase activity according to the manufacturer's instructions. A parallel set of fibroblast cultures were used to obtain cell numbers by direct cell counting using a hemocytometer. Luminescence units were converted to TGFβ1 concentration equivalents using a standard curve and normalized to fibroblast cell numbers.
Drug and chemical treatments
TGFβ1 (PeproTech) and TGFBR1 inhibitor (LY364947; Calbiochem) were prepared in tissue culture medium at concentrations of 5 ng/mL and 25 µ, respectively, and cells were treated for 90 min unless indicated otherwise. Endocytosis inhibitor treatments lasted 30 min. Filipin (caveolin-mediated endocytosis inhibitor; Sigma) was dissolved in dimethyl sulfoxide at a concentration of 1 mg/ml and diluted to a concentration of 1 µg/ml in media just before use. MDC (clathrin-mediated endocytosis inhibitor; Sigma) was dissolved in DMSO at a concentration of 50 m as a stock solution and used at a final concentration of 100 µ in media. To block protein synthesis, cycloheximide (Sigma) was added to the culture medium to a final concentration of 20 µg/ml for the indicated time. Proteasome inhibitor (lactacystin) and lysosome inhibitor (ammonium chloride) were purchased from Sigma and added to the media to final concentrations of 10 µ and 10 m, respectively, for 8 h. For these experiments, equal numbers of cells were grown in 10 mm tissue culture dishes to 90-100% confluence. Cells were treated with the various reagents for the indicated times and were processed for IB or ELISA.
IB and antibodies
Media samples were collected with a protease inhibitor cocktail (Sigma) after treating the cultured dermal fibroblasts overnight with serum-free media. Amicon Ultra-15 centrifugal filter units (Millipore) were used to concentrate media samples. Fibroblasts were lysed in CelLytic™ M (Sigma) with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific) to study intracellular pathways. For studying membrane proteins, the cell lysates were prepared using a The following antibodies were used: anti-LTBP4 (PA5-21378; Thermo Scientific), anti-FBN1 (anti-rabbit antiserum raised against the proline-rich region of FBN1, a gift of Dr Robert P. Mecham), anti-fibronectin (M002; Takara), anti-SMAD2 (3122; Cell Signaling), anti-pSMAD2 (3101; Cell Signaling), anti-ERK (4695s Cell Signaling), anti-pERK (4377 Cell Signaling), anti-SMAD6 (SAB1406098; Sigma), anti-SMAD7 (ST1625; Millipore), anti-TGFBR1 (3712; Cell Signaling), anti-TGFBR2 (SAB4502958; Sigma or ab61213; Abcam) and anti-pTGFBR1 (ab112095, Abcam), goat anti-mouse horse radish peroxidase (HRP; 115-035-003; Jackson & Immunology), goat anti-rabbit HRP (PAI-20391, Thermo).
Co-IP
Cell extracts from dermal fibroblasts of Control 3 and Patient 2 were prepared using the IP Lysis solution included in the Pierce Co-IP kit (Thermo, IL, USA). Anti-TGFBR2 antibody (40 μg, AF241, R&D, MN, USA) was used to prepare AminoLink Plus Coupling Resin for antibody immobilization. The antibody-coupled resin was incubated with cell lysates (1 mg total protein) overnight at 4°C with rotation. Washing and elution were performed according to the manufacturer's instructions. Eluted proteins were mixed with sample buffer, separated by SDS-PAGE and probed using an LTBP4 (AF2885, R&D) antibody. Separate aliquots of the cell extract were analyzed by IB for TGFBR2 and LTBP4 as input controls.
ELISA
TGFBR1 and TGFBR2 levels in the lysates extracted from cells treated with cycloheximide (Sigma) were measured using commercial ELISA kits (DY241 R&D Systems and SEA397 Hu CloudClone Corp., respectively). The procedures were performed according to the manufacturer's instructions. All of the measurements were performed in triplicate for each sample. The optical density at 450 nm (OD450) was measured using an ELISA reader.
LTBP4 knockdown
To silence LTBP4 expression in human dermal fibroblasts, an antisense MO, was designed to target the donor splice site of the first exon shared by all major LTBP4 transcript isoforms: NM_003573 (LTBP4L1, exon 5), NM_001042544 (LTBP4L2, exon 5) and NM_001042545 (LTBP4S, exon 2). The sequence complementary to the intron and exon shown in normal type and italic, respectively: 5′-GGCCACCCTTTCCTCACCGTGCTCG-3′. Treatment with this morpholino was expected to result in the skipping of exon 5, leading the elimination of the first epidermal growth factor-like domain of LTBP4, thought to be essential for the correct folding of the protein. A control morpholino was designed by mutating key residues in the LTBP4 MO, as shown by lower case letters: 5′-GGCgAgCCTTTCgTCAgCcTGCTCG-3′. MOs were delivered into human dermal fibroblasts from a healthy individual (Control 3, Table 2 ) using the Endo-Porter peptide delivery system (Gene Tools). For single delivery, cells were treated with 4 µ EndoPorter and 4.5 µ MO for 2 days, and given fresh media for 2 days prior to collecting the samples. For double delivery, cells were treated with the first dose for 2 days, given fresh media for 2 days, treated with a second dose for 2 days and given fresh media for 1 day prior to collecting samples. Media, membrane protein lysate and cytosol protein lysates were used for IB.
Recombinant LTBP4 overexpression
Control lentiviral construct pLOC-TurboRFP and pLOC-LTBP4 containing the complementary DNA (cDNA) corresponding to reference sequence NM_003573 were purchased from Thermo Scientific. A Myc-(His) 6 tag was engineered to the 3′-end of the pLOC-LTBP4 by polymerase chain reaction. The resulting pLOC-LTBP4-MycHis construct was transfected into HEK293 cells and subjected to selection with 8 μg/mL blasticidin for 3 weeks. Using limiting dilution, 32 clones were isolated from the stably transfected cells, and conditioned media and cell lysates from the clones were tested by ELISA for the expression of LTBP4 and the Myc tag. Eight clones showing the highest expression by ELISA were further tested by IB for LTBP4 and the Myc tag, and clone C13 was selected for subsequent experiments. HEK293 cells stably transfected with pLOC-TurboRFP served as negative controls. Conditioned media were collected from transfected HEK293 cells 5 days after confluence, and centrifuged to remove the cell debris. Conditioned media were mixed with fresh growth media 1:1 and used for LTBP4 mutant dermal fibroblast culture (Patient 4 in Table 2 ) for 7 days. At 7 days of treatment, membrane protein and cytosol protein extracts were collected as described above.
Immunofluorescent staining
Cultured human dermal fibroblasts at 90% confluency were stained for TGFBR1 (1:200; SAB4502958; Sigma) and LAMP1 (1:100; H4A3; DSHB, Iowa City, IA, USA). Cells on coverslips were fixed with PBS containing 4% paraformaldehyde at room temperature for 15 min. Incubation was performed overnight in 3% bovine serum albumin with 1% donkey serum to block nonspecific staining. Samples were incubated with primary antibodies (anti-TGFBR1 and anti-LAMP1) for 16 h at 4°C. Secondary antibodies were donkey anti-rabbit Alexa 488 (Invitrogen, Carlsbad, CA) and donkey anti-mouse Alexa 594 (Invitrogen, Carlsbad, CA) and the incubation time was 1 h at room temperature. Coverslips were rinsed three times with PBS and mounted with Cytoseal-60 mounting media. Specimens were examined and photographed by using a fluorescence photomicroscope (Leica DM5000B; Leica Microsystems, Richmond, IL, USA).
Knockout mouse experiments
The animal studies were conducted at the National Taiwan University Medical College and Hospital and were approved by the institutional animal care and use committee. The Ltbp4S −/− mouse line used in the study was previously described (3, 6) and was maintained on a C57BL/6J genetic background. Ltbp4S −/− mice and WT littermates, 3-4 weeks in age, were injected intraperitoneally with 4.2 mg/kg of TGFBR1 inhibitor (SB431542; Sigma-Aldrich, St. Louis, MO) (10, 16) . Controls were injected with PBS. Animals were sacrificed 6 h after injection and skin tissue samples were harvested and homogenized in radioimmunoprecipitation assay (RIPA) buffer [25 m TrisHCl pH 7.6, 150 m NaCl, 1% NP-40 (nonyl phenoxypolyethoxylethanol), 1% sodium deoxycholate, 0.1% sodium dodecylsulfate] supplemented with Halt Protease and Phosphatase Inhibitor Cocktails (Thermo Scientific). Protein extracts were processed for IB as described above.
Statistical analysis
P values were calculated by analysis of variance (ANOVA) with a post-hoc test or independent t-tests, as indicated in the figure legends. Analysis was performed with SPSS (Statistical Package for the Social Sciences) software (IBM, v.21) or Microsoft Excel. Values are expressed as the mean ± standard error of the mean (SEM). Results with P<0.05 were considered to be statistically significant. Areas under the curves in Figure 5 were calculated using the spline method included in the miscellaneous esoteric statistical scripts (MESS, http://cran.r-project.org/web/packages/ MESS/index.html) implemented in the statistical programming language R.
